Momenta Pharmaceuticals and Gilead Sciences Brace for More Competition
September 28 2011 - 8:16AM
Marketwired
The Paragon Report examines investing opportunities in the
Biotechnology and Drugs industry and provides equity research on
Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) and Gilead Sciences,
Inc. (NASDAQ: GILD). Access to the full company reports can be
found at:
www.paragonreport.com/MNTA
www.paragonreport.com/GILD
With several patent cliffs looming, companies in the
Biotechnology and Drugs sector are adopting different strategies to
ensure their own health once several drugs open up to generic
copies. One major trend has been to focus on emerging healthcare
markets where growth is strong in order to help offset upcoming
domestic uncertainty. Future growth of the pharmaceutical industry
is expected to take place in emerging markets including India,
China, Brazil, South Africa and others. This is because the
economies of these countries are booming and the middle class in
these nations continues to rapidly grow. "Emerging market activity
will be a source of out-performance for pharma stocks," thinks Dr.
Gbola Amusa, Managing Director, Global Pharmaceuticals Sector
Co-ordinator and Head of European Pharmaceuticals Research at UBS.
"Emerging markets for pharma are now just big enough to matter,"
said Dr. Amusa. "They are up from 5% of [Big Pharma's] business
five years ago to 20-30 percent."
The Paragon Report provides investors with an excellent first
step in their due diligence by providing daily trading ideas, and
consolidating the public information available on them. For more
investment research on the Biotechnology and Drugs industry
register with us free at www.paragonreport.com and get exclusive
access to our numerous stock reports and industry newsletters.
Momenta Pharmaceuticals is a biotechnology company specializing
in the characterization and process engineering of complex
molecules. These complex molecules include proteins, polypeptides,
and cell surface polysaccharides such as heparan-sulfate
proteoglycans (HSPGs). A week ago the company said it is suing
three generic drugmakers for allegedly infringing patents used to
produce its generic version of Lovenox, a popular blood thinning
drug.
Gilead Sciences focuses on the development and commercialization
of human therapeutics for life threatening diseases. The Company
has operations in North America, Europe and Asia Pacific.
The Paragon Report has not been compensated by any of the
above-mentioned publicly traded companies. Paragon Report is
compensated by other third party organizations for advertising
services. We act as an independent research portal and are aware
that all investment entails inherent risks. Please view the full
disclaimer at http://www.paragonreport.com/disclaimer.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From May 2024 to Jun 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Jun 2023 to Jun 2024